tirsdag 11. januar 2022

Beijing and Moscow are losing the vaccine diplomacy battle

The spread of the omicron variant has hit the world of coronavirus vaccine diplomacy hard. And the impact will be felt most keenly in Beijing and Moscow, as Chinese and Russian vaccines struggle with data showing they are less effective against the fast-spreading variant, dimming hopes for wider global uptake of their product.

The two most widely available Chinese coronavirus vaccines use technology that uses an inactivated version of the virus to produce an immune response — an older though more established technology than the messenger RNA platform used by vaccines widely available in the United States and Europe.

However, some studies now suggest that two doses of these vaccines, which are produced by Sinopharm and Sinovac, may provide relatively lower protection against omicron. The Post’s Eva Dou and Lyric Li reported Monday that China is facing the looming question of how to administer booster shots to its population of 1.4 billion, of whom more than 80 percent have been vaccinated, mostly with Sinopharm and Sinovac.